Q3 Earnings Forecast for INTS Issued By HC Wainwright

Intensity Therapeutics Inc. (NASDAQ:INTS) – HC Wainwright issued their Q3 2026 EPS estimates for Intensity Therapeutics in a research report issued on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($1.11) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Intensity Therapeutics’ Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.77) EPS, FY2029 earnings at ($0.94) EPS and FY2030 earnings at ($0.54) EPS.

Intensity Therapeutics (NASDAQ:INTS) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24).

INTS has been the subject of several other reports. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Finally, Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Intensity Therapeutics Price Performance

INTS stock opened at $4.20 on Thursday. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. The stock has a market cap of $13.69 million, a PE ratio of -1.18 and a beta of 2.76. Intensity Therapeutics has a 1 year low of $3.51 and a 1 year high of $43.50. The stock has a 50-day moving average price of $4.28 and a two-hundred day moving average price of $5.40.

Institutional Investors Weigh In On Intensity Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in INTS. Legacy Advisors LLC bought a new position in shares of Intensity Therapeutics during the 4th quarter worth approximately $63,000. Mesirow Financial Investment Management Inc. increased its holdings in Intensity Therapeutics by 25.5% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after purchasing an additional 51,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after buying an additional 201,357 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Intensity Therapeutics in the 4th quarter worth $26,000. Finally, State Street Corp increased its stake in Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares during the last quarter. Institutional investors own 3.74% of the company’s stock.

Key Headlines Impacting Intensity Therapeutics

Here are the key news stories impacting Intensity Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $7 from $5 and reiterated a “Buy” rating. The new target implies substantial upside from recent trading levels and is the clearest positive development for Intensity Therapeutics. StreetInsider analyst commentary
• Positive Sentiment: HC Wainwright projected quarterly 2027 losses of $0.21 to $0.26 per share while maintaining its Buy rating and $7 target. Although the estimates still reflect ongoing losses, the valuation stance suggests the firm expects longer-term potential from the company’s pipeline. MarketBeat analyst estimates
• Neutral Sentiment: Brookline Capital Markets raised its FY2030 EPS forecast to $13.27 from $12.72, indicating significant long-term earnings potential if Intensity Therapeutics’ development programs succeed. However, this forecast is distant and may have limited immediate influence on trading.
• Negative Sentiment: Brookline lowered its EPS forecasts for FY2026, FY2027 and FY2028 to losses of $3.41, $2.41 and $6.01 per share, respectively. It also cut its Q3 and Q4 2026 estimates to losses of $0.77 and $0.71 per share, signaling expectations for greater near-term cash burn and weaker profitability. MarketBeat Brookline Capital Markets estimates

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.